Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’

被引：0
|
作者：
K-L G Spindler
N Pallisgaard
R F Andersen
A Jakobsen
机构：
[1] Vejle Hospital,Department of Oncology
[2] Danish Colorectal Cancer Group South,Department of Biochemistry
[3] Vejle Hospital,undefined
[4] Kabbeltoft 25,undefined
[5] Vejle Hospital,undefined
[6] Current address: Department of Oncology,undefined
[7] Aarhus University Hospital,undefined
[8] Aarhus,undefined
[9] Denmark,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2380 / 2380
相关论文
共 50 条
  • [21] Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer
    Rossi, Sabrina
    Pagliaro, Arianna
    Finocchiaro, Giovanna
    Marinello, Arianna
    Giordano, Laura
    Bria, Emilio
    Stefani, Alessio
    Vitale, Antonio
    Toschi, Luca
    D'Argento, Ettore
    Santoro, Armando
    FUTURE ONCOLOGY, 2024, 20 (07) : 373 - 380
  • [22] Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts
    Reissig, Timm M.
    Ladigan-Badura, Swetlana
    Steinberg, Anja
    Maghnouj, Abdelouahid
    Li, Ting
    Verdoodt, Berlinda
    Liffers, Sven T.
    Pohl, Michael
    Wolters, Heiner
    Teschendorf, Christian
    Viebahn, Richard
    Admard, Jakob
    Casadei, Nicolas
    Tannapfel, Andrea
    Schmiegel, Wolff
    Hahn, Stephan A.
    Vangala, Deepak B.
    MOLECULAR ONCOLOGY, 2023, 17 (11) : 2396 - 2414
  • [23] SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer
    Montal, R.
    Merche, M. -V.
    Anta, B.
    Martinez, N.
    Santos, C.
    Sanjuan, X.
    Paules, M. J.
    Perez Martin, F. J.
    Azuara, D.
    Salazar, R.
    Rojas, J. M.
    ANNALS OF ONCOLOGY, 2015, 26
  • [24] Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan
    Spindler, Karen-Lise Garm
    Pallisgaard, Niels
    Vogelius, Ivan
    Jakobsen, Anders
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 1177 - 1185
  • [25] Response to the Comment on "Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases."
    Margonis, Georgios Antonios
    Andreatos, Nikolaos
    Wolfgang, Christopher L.
    Weiss, Matthew J.
    ANNALS OF SURGERY, 2019, 269 (04) : E49 - E51
  • [26] Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan
    Pallisgaard, N.
    Spindler, K. G.
    Vogelius, I. S.
    Jakobsen, A. K. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Avutometinib plus cetuximab after chemotherapy in patients with KRAS-mutated metastatic colorectal cancer: Results of phase 1 dose escalation.
    Gujarathi, Rushabh
    Polite, Blase N.
    Cursio, John
    Desgardin, Aurelie
    El-Naggar, Ryan
    Savaiano, Cindy
    Wherity, Katherine
    Shaik, Afnan
    Nambiar, Chetan
    Arndt, Nicole
    Serbas, Lianna
    Neerukonda, Anu Radha
    Liao, Chih-Yi
    Shergill, Ardaman
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 199 - 199
  • [28] Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
    Donatella Lucchetti
    Ina Valeria Zurlo
    Filomena Colella
    Claudio Ricciardi-Tenore
    Mariantonietta Di Salvatore
    Giampaolo Tortora
    Ruggero De Maria
    Felice Giuliante
    Alessandra Cassano
    Michele Basso
    Antonio Crucitti
    Ilaria Laurenzana
    Giulia Artemi
    Alessandro Sgambato
    Scientific Reports, 11
  • [29] Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
    Lucchetti, Donatella
    Zurlo, Ina Valeria
    Colella, Filomena
    Ricciardi-Tenore, Claudio
    Di Salvatore, Mariantonietta
    Tortora, Giampaolo
    De Maria, Ruggero
    Giuliante, Felice
    Cassano, Alessandra
    Basso, Michele
    Crucitti, Antonio
    Laurenzana, Ilaria
    Artemi, Giulia
    Sgambato, Alessandro
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [30] The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
    Hochster, Howard S.
    Messersmith, Wells A.
    O'Neil, Bert H.
    Groshen, Susan G.
    Lenz, Heinz-Josef
    Cohen, Deirdre Jill
    Denlinger, Crystal Shereen
    Gold, Philip Jordan
    Eckhardt, S. Gail
    Locker, Gershon Y.
    Ames, Patricia
    McKinley, Marti
    Leichman, Lawrence P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345